Vaccine News and Research

Latest Vaccine News and Research

Genencor Sells Its Therapeutic Vaccine Program to Innogenetics

Genencor International, Inc. today announced that it has agreed to sell its therapeutic vaccine program to Belgian biotechnology company Innogenetics N.V. Innogenetics will develop and commercialize current product candidates in Genencor’s vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor.

30 Mar 2004

Researchers tap modified plant viruses to ward off cervical cancer-causing infections

New vaccinations to prevent infections that lead to cervical cancer and targeted therapeutics aimed at breast cancer were examples of research highlights presented by scientists today at the 95th Annual Meeting of the American Association for Cancer Research. Scientists described advances that feed into the drug development 'pipeline,' and show strong promise for controlling existing tumors or addressing the pathogen that causes tumors.

29 Mar 2004

Novel vaccine technology to suppress the growth of certain tumors

MedImmune, Inc. and Cerus Corporation have announced preclinical results demonstrating the effectiveness of a novel therapeutic vaccine technology in suppressing the growth of certain tumors.

From Baxter International Inc. 29 Mar 2004

Children with sickle cell disease are living longer, dying less often from their disease

Children with sickle cell disease, an inherited red blood-cell disorder, are living longer, dying less often from their disease and contracting fewer fatal infections than ever before, researchers at UT Southwestern Medical Center at Dallas report. Their study, which will appear in the June edition of the scientific journal Blood, is the first to evaluate survival rates of children receiving the most modern treatments for sickle cell disease. It's also one of the largest published sickle cell studies to date. Researchers followed more than 700 Dallas-area children with the disease over two decades.

25 Mar 2004

Partnership to improve TB vaccine, Bacillus Calmette-Guérin (BCG)

Crucell N.V.and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, announced today a new collaboration on the pre-clinical and clinical development of candidate tuberculosis (TB) vaccines. Aeras has agreed to provide Crucell up to USD$2.9 million contingent upon meeting certain development milestones, for development of TB vaccine candidates.

25 Mar 2004

First US Tests of Bird-Flu Vaccine in Humans

Doctors are beginning the first test in the United States of a vaccine designed to protect people against one form of bird flu should an outbreak of the virus occur in humans. While the vaccine under study is not designed to protect against the precise bird-flu virus causing the current outbreak in poultry and in people, scientists will learn whether it protects against another strain of the virus that infects birds and people.

24 Mar 2004

EU gives 32 million Euro for vaccines to stop tuberculosis

The European Commission today launched the largest-ever collaborative tuberculosis (TB) initiative for World TB-day, March 24. Fifty-two research teams from academia and industry from 15 European and African countries are joining forces with the European Commission to help eradicate TB. Globally, TB kills 2 million people a year, with one-third of the world's population currently infected with the bacillus, Mycobacterium tuberculosis (Mtb). While most cases and deaths occur in developing countries, resistant Mtb strains are mainly found among the poorest people in developed countries, as incomplete treatment increases drug resistance. The European Union is confronting the re-emerging threat of TB by investing €32 million in two overlapping research projects. This cash will be used in an accelerated effort to develop new, effective vaccines to fight TB.

23 Mar 2004

Scientists identify genetic changes during infection by tuberculosis

Researchers at the Center for Biomedical Inventions at UT Southwestern Medical Center at Dallas have identified the genetic changes that Mycobacterium tuberculosis, the bacterium that causes tuberculosis, undergoes during infection of a living host.

22 Mar 2004

Pharmexa vaccine is designed to induce antibody responses against the HER-2 protein

Pharmexa presents data from the HER-2 Protein AutoVac™ breast cancer trial at a Conference in Hamburg Summary: Pharmexa is presenting data from the first clinical trial in USA with the HER-2 Protein AutoVac™ vaccine at the 4th European Breast Cancer Conference (EBCC) in Hamburg, Germany.

22 Mar 2004

Mouse antibodies neutralise SARS virus

The mouse immune system develops antibodies capable of single-handedly neutralizing the SARS virus, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) report in the April 1 issue of the Journal of Virology, now available online. NIAID is part of the National Institutes of Health (NIH).

22 Mar 2004

Vaccine News and Research

Latest Vaccine News and Research

Genencor Sells Its Therapeutic Vaccine Program to Innogenetics

Researchers tap modified plant viruses to ward off cervical cancer-causing infections

Novel vaccine technology to suppress the growth of certain tumors

Children with sickle cell disease are living longer, dying less often from their disease

Partnership to improve TB vaccine, Bacillus Calmette-Guérin (BCG)

First US Tests of Bird-Flu Vaccine in Humans

EU gives 32 million Euro for vaccines to stop tuberculosis

Scientists identify genetic changes during infection by tuberculosis

Pharmexa vaccine is designed to induce antibody responses against the HER-2 protein

Mouse antibodies neutralise SARS virus

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Vaccine News and Research

Latest Vaccine News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in